Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$626M |
| 2 |
Warner Bros
WBD
|
+$447M |
| 3 |
Apple
AAPL
|
+$436M |
| 4 |
RTX Corp
RTX
|
+$434M |
| 5 |
Constellation Brands
STZ
|
+$320M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.13B |
| 2 |
Microsoft
MSFT
|
+$502M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$436M |
| 4 |
EXAS
Exact Sciences
EXAS
|
+$415M |
| 5 |
EA
Electronic Arts
EA
|
+$388M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 9.75% |
| 2 | Industrials | 9.36% |
| 3 | Consumer Discretionary | 8.52% |
| 4 | Healthcare | 7.75% |
| 5 | Financials | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
876
Aclaris Therapeutics
ACRS
$945M
| $12.6M | 0.02% |
+3,361,328
| New | +$11.3M |
|
877
Aurora
AUR
$11.6B
| $12.6M | 0.02% |
3,053,389
+2,835,707
| +1,303% | +$12.5M |
|
878
Ericsson
ERIC
$33.6B
| $12.5M | 0.02% |
1,111,485
-1,013,578
| -48% | -$11M |
|
879
PUT
Vita Coco
COCO
$3.7B
| $12.5M | 0.02% |
+261,000
| New | +$14.2M |
|
880
Teekay Tankers
TNK
$3.14B
| $12.5M | 0.02% |
+170,519
| New | +$11.4M |
|
881
PUT
Dollar General
DG
$27.1B
| $12.5M | 0.02% |
105,300
-160,500
| -60% | -$22.9M |
|
882
Perspective Therapeutics
CATX
$376M
| $12.5M | 0.02% |
+2,994,460
| New | +$12.7M |
|
883
CALL
Applovin
APP
$103B
| $12.4M | 0.02% |
31,200
-3,600
| -10% | -$1.74M |
|
884
Enbridge
ENB
$109B
| $12.4M | 0.02% |
229,054
-413,111
| -64% | -$21M |
|
885
PUT
Carnival Corporation Ltd
CCL
$35.6B
| $12.4M | 0.02% |
478,400
-198,300
| -29% | -$5.78M |
|
|
IRD
886
Opus Genetics
IRD
$348M
| $12.4M | 0.02% |
2,718,029
| – | – |
|
887
PUT
Spotify
SPOT
$113B
| $12.4M | 0.02% |
25,500
+16,100
| +171% | +$8.08M |
|
888
Sociedad Química y Minera de Chile
SQM
$22.6B
| $12.3M | 0.02% |
152,429
-239,623
| -61% | -$18.2M |
|
889
CALL
iShares MSCI South Korea ETF
EWY
$27.8B
| $12.3M | 0.02% |
100,000
+70,000
| +233% | +$8.76M |
|
890
Ovid Therapeutics
OVID
$562M
| $12.3M | 0.02% |
5,533,073
+5,208,073
| +1,602% | +$9.31M |
|
891
CALL
Deere & Co
DE
$171B
| $12.3M | 0.02% |
21,800
+9,900
| +83% | +$5.59M |
|
892
PUT
Delta Air Lines
DAL
$54.5B
| $12.2M | 0.02% |
184,000
-137,300
| -43% | -$9.24M |
|
893
Lowe's Companies
LOW
$121B
| $12.2M | 0.02% |
51,740
-332,598
| -87% | -$86.7M |
|
894
PUT
Salesforce
CRM
$170B
| $12.2M | 0.02% |
65,300
-11,300
| -15% | -$2.34M |
|
895
PUT
Wayfair
W
$14.3B
| $12.2M | 0.02% |
161,900
-229,100
| -59% | -$20.7M |
|
896
Direxion NASDAQ-100 Equal Weighted Index ETF
QQQE
$1.45B
| $12.2M | 0.02% |
+123,448
| New | +$12.7M |
|
897
Enliven Therapeutics
ELVN
$4.45B
| $12.2M | 0.02% |
+310,025
| New | +$8.59M |
|
898
JetBlue
JBLU
$1.9B
| $12.1M | 0.02% |
2,740,526
+2,721,379
| +14,213% | +$13.8M |
|
899
Crane Co
CR
$11.9B
| $12.1M | 0.02% |
70,786
-114,396
| -62% | -$22M |
|
|
PRA
900
DELISTED
ProAssurance
PRA
| $12.1M | 0.02% |
488,074
-551,827
| -53% | -$13.5M |
|
Similar funds
Dmitry Balyasny's Q1 2026 Portfolio in Review
As of Q1 2026, Dmitry Balyasny held 3,716 positions worth $77.1B, down 2.1% from $78.8B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Dmitry Balyasny withdrew a net $2.68B in Q1 2026, closing 911 positions and reducing 1,056 holdings. Its most notable exit was iShares Core S&P 500 ETF, an estimated $1.13B position sold in full.
By sector, the portfolio is most concentrated in Technology at 9.7% of assets, down from 12% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in Silicon Laboratories worth $257M.
- Dmitry Balyasny's largest Q1 2026 buy was Silicon Laboratories: 1,233,893 shares worth $257M.
- Dmitry Balyasny added most to Meta Platforms (Facebook) in Q1 2026, an estimated $626M increase.
- Dmitry Balyasny's biggest Q1 2026 reduction was Microsoft, cutting an estimated $502M.
- Dmitry Balyasny fully exited iShares Core S&P 500 ETF in Q1 2026, selling an estimated $1.13B.
- Dmitry Balyasny's ten largest holdings make up 17% of its $77.1B portfolio in Q1 2026.
- Dmitry Balyasny opened 704 new positions and closed 911 in Q1 2026.
- Dmitry Balyasny's portfolio value fell 2.1% quarter-over-quarter to $77.1B.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.